Literature DB >> 1543674

Treatment of cutaneous sporotrichosis with terbinafine.

P R Hull1, H F Vismer.   

Abstract

Terbinafine, an allylamine antifungal agent, has been shown to have excellent in-vitro activity against dermatophytes. Several other fungi of importance also show in-vitro sensitivity. Because terbinafine is fungicidal rather than fungistatic in action, its efficacy in treating such fungal infections requires evaluation. Five patients with cutaneous sporotrichosis were treated with 250 mg of terbinafine twice daily. All of the patients were cured. Overall, the clinical response was rapid. In three patients, negative culture was achieved within 8 weeks; in the other two, negative culture was obtained at 12 and 32 weeks, respectively. Terbinafine was well tolerated, although one patient developed erectile dysfunction while receiving treatment. This was completely resolved on stopping the treatment. The treatment of sporotrichosis is also reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1543674     DOI: 10.1111/j.1365-2133.1992.tb00011.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

1.  In vitro susceptibilities of isolates of Sporothrix schenckii to itraconazole and terbinafine.

Authors:  Lidiane Meire Kohler; Paulo César Fialho Monteiro; Rosane Christine Hahn; Júnia Soares Hamdan
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 2.  Successful Treatment of Canine Sporotrichosis with Terbinafine: Case Reports and Literature Review.

Authors:  Paula Gonçalves Viana; Anna Barreto Fernandes Figueiredo; Isabella Dib Ferreira Gremião; Luisa Helena Monteiro de Miranda; Isabela Maria da Silva Antonio; Jéssica Sepulveda Boechat; Ana Caroline de Sá Machado; Manoel Marques Evangelista de Oliveira; Sandro Antonio Pereira
Journal:  Mycopathologia       Date:  2017-12-08       Impact factor: 2.574

Review 3.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis.

Authors:  Glaucia Francesconi; Antonio Carlos Francesconi do Valle; Sonia Lambert Passos; Mônica Bastos de Lima Barros; Rodrigo de Almeida Paes; André Luiz Land Curi; José Liporage; Cássio Ferreira Porto; Maria Clara Gutierrez Galhardo
Journal:  Mycopathologia       Date:  2010-11-21       Impact factor: 2.574

5.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

Review 6.  Sporotrichosis: an overview and therapeutic options.

Authors:  Vikram K Mahajan
Journal:  Dermatol Res Pract       Date:  2014-12-29

7.  Sporotrichosis by Sporothrix schenckii senso stricto with itraconazole resistance and terbinafine sensitivity observed in vitro and in vivo: Case report.

Authors:  Rodrigo Vettorato; Daiane Heidrich; Fernanda Fraga; Amanda Carvalho Ribeiro; Danielle Machado Pagani; Carina Timotheo; Tais Guarienti Amaro; Gerson Vettorato; Maria Lúcia Scroferneker
Journal:  Med Mycol Case Rep       Date:  2017-10-28

Review 8.  Sporotrichosis successfully treated with terbinafine and potassium iodide: case report and review of the literature.

Authors:  Basak Coskun; Yunus Saral; Nusret Akpolat; Arzu Ataseven; Demet Ciçek
Journal:  Mycopathologia       Date:  2004-07       Impact factor: 3.785

9.  Efficacy of terbinafine and itraconazole on a experimental model of systemic sporotrichosis.

Authors:  Ana Raquel Mano Meinerz; Melissa O Xavier; Marlete Brum Cleff; Isabel Martins Madrid; Márcia Oliveira Nobre; Mário Carlos Araújo Meireles; João Roberto Braga de Mello
Journal:  Braz J Microbiol       Date:  2008-12-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.